Ana Aurora Torres obtained a Bachelor’s degree in Biomedical Sciences and a Master’s degree in Biomedicine at the University of Barcelona (UB). She joined the Cancer Cell Biology Research Group as a Final Degree Project student in 2022 and stayed for her MSc the following year. Since October 2023, she is performing her Ph.D. studies under the supervision of Dr. Vanessa Soto-Cerrato.
Her current work is focused on evaluating the inhibition of cytoprotective autophagy as a new therapeutic approach to overcome resistance to conventional treatments in lung cancer.
ORCID ID: 0000-0003-0512-8161
Publications
- Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapies. Benítez-García C, Martínez-García D, Kotev M, Pérez-Hernández M, Westermaier Y, Díaz L, Korrodi-Gregório L, Fontova P, Torres AA, Pérez-Tomás R, García-Valverde M, Quesada R, Soliva R, Soto-Cerrato V. Biomed Pharmacother, 2025.
- A Novel Late-Stage Autophagy Inhibitor That Efficiently Targets Lysosomes Inducing Potent Cytotoxic and Sensitizing Effects in Lung Cancer. Molero-Valenzuela A, Fontova P, Alonso-Carrillo D, Carreira-Barral I, Torres AA, García-Valverde M, Benítez-García C, Pérez-Tomás R, Quesada R, Soto-Cerrato V. Cancers, 2022.
